Levine James E. 4

What Happened

• James E. Levine, Chief Financial Officer of Kazia Therapeutics Ltd. (KZIA), received an award of 200,000 options over American Depositary Shares (ADSs) on June 19, 2026. The award was granted for no cash consideration and is reported as a derivative acquisition; the reported acquisition price is $0.
• The options have an exercise price of $13.86 per ADS and expire on June 19, 2029. This is a compensation grant (not a market purchase or sale) and does not involve immediate cash proceeds or sales of shares.

Key Details

• Transaction date: June 19, 2026 (reported on Form 4 filed June 23, 2026). Filing appears timely.
• Grant: 200,000 options over ADSs; exercise price $13.86 per ADS; grant consideration: $0; expiration: June 19, 2029.
• Vesting: 1/3 vested on June 1, 2026 (the “Commencement Date”); the remaining 2/3 vest in equal yearly tranches on each anniversary of the Commencement Date (i.e., fully vested over the subsequent two anniversaries).
• Forfeiture: All options will be forfeited if the reporting person voluntarily departs prior to the first anniversary of the Commencement Date (per footnote).
• Shares/options owned after the transaction: not specified in the provided filing details.

Context

• This was an option grant (compensation), not an exercise or sale. There is no immediate change in outstanding common shares unless and until options are exercised and shares issued.
• Such grants are commonly part of executive compensation and do not by themselves indicate the insider is buying or selling stock in the open market.